{
    "clinical_study": {
        "@rank": "124323", 
        "arm_group": [
            {
                "arm_group_label": "Stress only CardioPET\u2122", 
                "arm_group_type": "Experimental", 
                "description": "Group I will consist of 15-20 patients and will have CardioPET\u2122 imaging performed with a repeat identical stress component at \u2265 48 hours and \u2264 10 days after the initial stress MPI study. There should be no intervention or change in symptoms between the tests, and the patient must have an angiography scheduled to be performed within 30 days.\nThe analysis of the acquired imaging data will determine if CardioPET\u2122 is suitable for identifying myocardial flow defects that were observed in exercise or pharmacologic stress Tc-99m MPI imaging. The goal for this CardioPET\u2122 imaging group is to measure blood flow at near maximal stress."
            }, 
            {
                "arm_group_label": "Rest only CardioPET\u2122", 
                "arm_group_type": "Experimental", 
                "description": "Group II will consist of 15-20 subjects will have undergone either, stress, Tc-99m MPI study or stress-echocardiography indicating \u22652 segments of ischemia.  These patients must have been referred and scheduled for coronary angiography. If initial evaluation was performed with stress echocardiography, subjects will have either exercise or pharmacologic stress MPI.\nCardioPET\u2122 imaging in these subjects must be performed \u2265 48 hours and \u2264 10 days from the initial stress (stress MPI or echocardiography) at rest only.  An angiography must be scheduled to be performed within 30 days."
            }
        ], 
        "brief_summary": {
            "textblock": "The study is designed to evaluate how safe and how well an investigational imaging product\n      CardioPET\u2122 performs as compared to standard approved imaging products in assessing the\n      function of heart muscle in coronary artery disease patients."
        }, 
        "brief_title": "CardioPET as PET Imaging Agent to Assess Myocardial Perfusion and Fatty Acid Uptake in Known or Suspected CAD Subjects", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "The open label, phase II, multi center, study objectives are as follows:\n\n        -  To evaluate the diagnostic performance of CardioPET\u2122 in assessing myocardial perfusion\n           as compared to standard Tc-99m myocardial perfusion agents with coronary angiography as\n           the standard of reference for CAD.\n\n        -  To evaluate the safety of CardioPET\u2122 in known or suspected CAD subjects.\n\n        -  A secondary objective is to assess fatty acid uptake at rest and following stress."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must provide written informed consent prior to any study related procedures;\n\n          -  Male and female subjects over 30 years of age with known or suspected CAD;\n\n          -  Subjects have been evaluated as having known or suspected CAD by either exercise or\n             pharmacologic MPI or echocardiography with \u22652 segments of ischemia and have been\n             referred to coronary angiography for known or suspected CAD;\n\n          -  Subjects must be able to complete all evaluations within 30 days of Tc-99m MPI\n             imaging, and must be without any intervention or change in symptoms between the\n             tests.\n\n        Exclusion Criteria:\n\n          -  Past or present use of medications that target fatty acid uptake or metabolism, e.g.\n             Ranexa\u00ae (Ranolazine);\n\n          -  Acute changes in comparison to most recent ECG;\n\n          -  Suspected acute coronary syndrome;\n\n          -  Chronic renal failure (Cr > 2.5);\n\n          -  Anemia (Hgb < 10 within past 2 weeks);\n\n          -  NYHA Class III or IV Congestive heart failure;\n\n          -  Severe heart valve  disease;\n\n          -  Any exposure to any investigational drugs or devices, within 30 days prior to imaging\n             study;\n\n          -  Any acute or unstable physical or psychological disease judged by the Investigators\n             based on medical history or screening physical examination;\n\n        Female subjects only:\n\n          -  Subject that has a positive pregnancy test or is lactating or the possibility of\n             pregnancy cannot be ruled out prior to dosing.\n\n          -  Females not of child-bearing potential require confirmatory documentation in their\n             medical records or must have a negative pregnancy test within 4 hours prior to\n             receiving the test drug and agree to use an acceptable form of birth control for at\n             least 30 days following CardioPET\u2122 administration.\n\n        Male subjects:\n\n          -  Reliable contraception method from the first injection with the tracer until 3 months\n             after the last injection with the tracer. The following contraceptive method(s) is\n             (are) allowed during the study: Condom.\n\n          -  If your partner becomes pregnant during the study, you should immediately report this\n             to the investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01826773", 
            "org_study_id": "CardioPET\u2122 P-02", 
            "secondary_id": "2012-002261-36"
        }, 
        "intervention": {
            "arm_group_label": [
                "Stress only CardioPET\u2122", 
                "Rest only CardioPET\u2122"
            ], 
            "description": "CardioPET\u2122 will be intravenously injected to each subject as a single radio-labeled dose of up to 8 mCi (296 MBq).", 
            "intervention_name": "CardioPET\u2122", 
            "intervention_type": "Drug", 
            "other_name": [
                "trans-9-18F-Fluoro-3,4-Methyleneheptadecanoic Acid", 
                "FCPHA (Fluoro CycloPropyl Hexadecanoic Acid)"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Palmitic Acid"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "CardioPET", 
            "Coronary Artery Disease", 
            "Myocardial Perfusion Imaging", 
            "Coronary Angiography", 
            "Myocardial Fatty Acid Utilization"
        ], 
        "lastchanged_date": "November 1, 2013", 
        "link": {
            "description": "Click here for more information on CardioPET\u2122", 
            "url": "http://www.fluoropharma.com/"
        }, 
        "location": [
            {
                "contact": {
                    "email": "Pieter.De.Bondt@olvz-aalst.be", 
                    "last_name": "Pieter De Bondt, M.D.", 
                    "phone": "+32 53 72 44 77"
                }, 
                "facility": {
                    "address": {
                        "city": "Aalst", 
                        "country": "Belgium"
                    }, 
                    "name": "Dienst Nucleaire Geneeskunde, OLV Ziekenhuis Aalst"
                }, 
                "investigator": {
                    "last_name": "Pieter De Bondt, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sgoldman@ulb.ac.be", 
                    "last_name": "Serge Goldman, M.D.", 
                    "phone": "+32 2 5554711"
                }, 
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium"
                    }, 
                    "name": "Service de Medicine Nucleaire, CHU Erasme"
                }, 
                "investigator": {
                    "last_name": "Serge Goldman, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "david.vancraeynest@uclovain.be", 
                    "last_name": "David Vancraeynest, M.D.", 
                    "phone": "+32 2 764 28 03"
                }, 
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium"
                    }, 
                    "name": "Departement de Cardiologie, CU Saint-Luc"
                }, 
                "investigator": {
                    "last_name": "David Vancraeynest, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "olivier.gheysens@uzleuven.be", 
                    "last_name": "Olivier Gheysens, Professor", 
                    "phone": "+32-16-34.25 67"
                }, 
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium"
                    }, 
                    "name": "Nucleaire Geneesunde Gasthuisberg Leuven Hospital"
                }, 
                "investigator": {
                    "last_name": "Olivier Gheysens, Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rhustinx@chu.ulg.ac.be", 
                    "last_name": "Roland Hustinx, M.D.", 
                    "phone": "+32 43 66 72 00"
                }, 
                "facility": {
                    "address": {
                        "city": "Liege", 
                        "country": "Belgium"
                    }, 
                    "name": "Service de Medicine Nucleaire, Centre Hospitalier Univerisataire de Liege, Belgium"
                }, 
                "investigator": {
                    "last_name": "Roland Hustinx", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II Open-Labeled Study to Evaluate CardioPET\u2122 as a PET Imaging Agent for Evaluation of Myocardial Perfusion and Fatty Acid Uptake in Subjects With Coronary Artery Disease", 
        "overall_contact": {
            "email": "olivier.gheysens@uzleuvens.be", 
            "last_name": "Olivier Gheysens, Professor", 
            "phone": "+32-16-34.25.25 67"
        }, 
        "overall_contact_backup": {
            "email": "rhustinx@chu.ulg.ac.be", 
            "last_name": "Roland Hustinx, Professor", 
            "phone": "+32 43 66 72 00"
        }, 
        "overall_official": {
            "affiliation": "Nucleaire Geneesunde Gasthuisberg Leuven Hospital, Leuven, Belgium", 
            "last_name": "Olivier Gheysens, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Belgium: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The aim of this clinical protocol is to study CardioPET\u2122 as a PET imaging agent for evaluation of myocardial perfusion in subjects with known or suspected CAD with a single injection of CardioPET\u2122.\nThe primary efficacy endpoint for this phase II study is the sensitivity and specificity of CardioPET\u2122 compared to Myocardial Perfusion Imaging (MPI) using coronary angiography as the standard of reference for the detection of Coronary Artery Disease (CAD).", 
            "measure": "Primary Efficacy Endpoint- sensitivity and specificity of CardioPET\u2122", 
            "safety_issue": "No", 
            "time_frame": "One year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01826773"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Laboratory Testing- hematology, serum chemistry and urine analysis\nElectrocardiograms, Serial QT and QTc measurements\nPhysical Examinations\nVital signs-heart rate and systolic and diastolic blood pressure\nAdverse Event Assessments o", 
            "measure": "Primary safety endpoints comparing baseline (pre-injection) values to post-injection values for laboratory testing, electrocardiograms, serial QT, and QTc measurements, physical examinations, vital signs and adverse event assessments", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline (pre-injection) values to Post-injection values"
        }, 
        "source": "Fluoropharma, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fluoropharma, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}